Clinical Trial

Decitabine and Umbilical Cord Blood for Poor Graft Function Post Allo-HSCT

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated June 9, 2023 (before its estimated August 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
This randomized trial aimed at validating the efficacy and safety of low-dose decitabine, together with umbilical cord blood in PGF post allo-HSCT patients.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2022-12-29.
Trial Details
NCT Number NCT05669079
Lead Sponsor The First Affiliated Hospital of Soochow University
Conditions Poor Graft Function
Enrollment 100 participants
Start Date 2023-08-01
Primary Completion 2026-08-01 (estimated)
Study Completion 2026-11-01 (estimated)
Updated on ClinicalTrials.gov 2023-06-09